K562 tumor cells can directly stimulate these trained CD3+CD56+ NKT-like cells to release IFN-γ and enhance their killing ability, which also indicates the potential of cytokine training immunity for clinical tumor therapy. Here, NCAM1 is linked to neoplasm.